Atypical antipsychotics in bipolar depression: Potential mechanisms of action

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 5, 2005, Pages 40-48

  Yatham, Lakshmi N ^a   Goldstein, Jeffrey M ^b   Vieta, Eduard ^c   Bowden, Charles L ^d   Grunze, Heinz ^e   Post, Robert M ^f   Suppes, Trisha ^g   Calabrese, Joseph R ^h  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f Bipolar Collaborative Network   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DULOXETINE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; GLUTAMIC ACID; HALOPERIDOL; IMIPRAMINE; LITHIUM; LITHIUM CARBONATE; MIRTAZAPINE; MOOD STABILIZER; NEFAZODONE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PAROXETINE; PINDOLOL; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE; ZIPRASIDONE;

BIPOLAR DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; HUMAN; MANIA; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND MESSENGER; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; SECOND MESSENGER SYSTEMS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 21644461410     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (87)

1. Sassi RB, Soares JC. Emerging therapeutic targets in bipolar mood disorder. Expert Opin Ther Targets 2001;5:587-599
2. Post RM. The impact of bipolar depression. J Clin Psychiatry 2005;66(suppl 5):5-10
3. Calabrese JR, Hirschfeld RMA, Frye MA, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. J Clin Psychiatry 2004;65:1499-1504
4. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder [Revision]. Am J Psychiatry 2002;159 (suppl 4):1-50
5. Suppes T, Dennehy EB, Hirschfeld RMA, et al. The Texas Implementation of Medication Algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. In press
6. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Arch Gen Psychiatry 1973;29:420-425
7. Calabrese JR, Rapport DJ, Kimmel SE, et al. Controlled trials in bipolar I depression: focus on switch rates and efficacy. Eur Neuropsychopharmacol 1999;9(suppl 4):S109-S112
8. Grunze H, Kasper S, Goodwin G, et al., WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, pt 1: treatment of bipolar depression. World J Biol Psychiatry 2002;3:115-124
9. Yatham LN, Kennedy S, O'Donovan C, et al. 2005 Canadian Network for Mood and Anxiety Disorders: guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. In press
10. Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-512
11. Leverich G, Altshuler L, Frye M, et al. The range of hypo/manic severities on antidepressants: a randomized, double blind comparison of bupropion, sertraline, and venlafaxine using daily NIMH-LCM ratings. Acta Psychiatr Scand Suppl 2004;110:S39
12. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55: 391-393
13. Calabrese JR, Elhaj O, Gajwani P, et al. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 2005;66 (suppl 5):26-33
14. Goldstein J. Preclinical profile of Seroquel (quetiapine): an atypical anti-psychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwen GW, eds. Schizophrenia: Breaking Down the Barriers. New York, NY: John Wiley & Sons; 1996:177-208
15. Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004;65:1715-1719
16. Elhwuegi AS. Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:435-451
17. Shiah IS, Yatham LN. Serotonin in mania and in the mechanism of action of mood stabilizers: a review of clinical studies. Bipolar Disord 2000;2:77-92
18. Mahmood T, Silverstone T. Serotonin and bipolar disorder. J Affect Disord 2001,66:1-11
19. Kinney GG, Taber MT, Gribkoff VK. The augmentation hypothesis for improvement of antidepressant therapy: is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol Neurobiol 2000;21:137-152
20. Brousse G, Schmitt A, Chereau I, et al. Interest of the use of pindolol in the treatment of depression: review [in French]. Encephale 2003;29 (4 pt 1):338-350
21. 1A receptors by fluoxetine despite the loss of firing-dependent serotonergic input: electrophysiological and neurochemical studies. Synapse 2001;41:49-57
22. Bhagwagar Z, Rabiner EA, Sargent PA, et al. Persistent reduction in brain serotonin 1A receptor binding in men who have recovered from depression measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 2004;9:386-392
23. Brevets WC, Frank E, Price IC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999;46:1375-1387
24. Sargent PA, Kjaer KH, Bench CI, et al. Brain serotoninl A receptor binding measured by positron emission tomography with [11C] WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57:174-180
25. Yatham LN, Liddle PF, Shiah IS, et al. Brain serotonin2 receptors in major depression: a positron emission tomography study. Arch Gen Psychiatry 2000;57:850-858
26. 2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry 2004;55:217-224
27. Eison AS, Yocca FD, Gianutsos G. Effect of chronic administration of antidepressant drugs on 5-HT2-mediated behavior in the rat following noradrenergic or serotonergic denervation. J Neural Transm Gen Sect 1991;84:19-32
28. Meyer IH, Kapur S, Eisfeld B, et al. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 2001;158:78-85
29. Yatham LN, Liddle PF, Dennie I, et al. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Arch Gen Psychiatry 1999;56:705-711
30. Mischoulon D, Dougherty DD, Bottonari KA, et al. An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. Psychiatry Res 2002;116:151-161
31. 2 receptors: a PET study. Presented at the 52nd annual meeting of the Canadian Psychiatric Association. October 31-November 3, 2002; Banff, Canada
32. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965;122:509-522
33. Leonard BE. The role of noradrenaline in depression: a review. J Psychopharmacol 1997;11(suppl 4):S39-S47
34. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990
35. Hajos M, Fleishaker JC, Filipiak-Reisner JK, et al. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 2004;10:23-44
36. Zajecka IM, Albano D. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry 2004;65(suppl 17):11-18
37. Kent IM. SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-918
38. Rogoz Z, Wrobel A, Dlaboga D, et al. Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. J Physiol Pharmacol 2002;53:105-116
39. Yatham LN, Liddle PF, Shiah IS, et al. PET study of [(18)F]6-fluoro-L- dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry 2002;159:768-774
40. Prange AJ, Wilson IC, Lynn CW, et al. L-Tryptophan in mania: contribution to a permissive hypothesis of affective disorders. Arch Gen Psychiatry 1974;30:56-62
41. Wilner P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DI, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:921-931
42. Suhara T, Nakayama K, Inoue O, et al. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl) 1992;106:14-18
43. Reddy PL, Khanna S, Subhash MN. CSF amine metabolites in depression. Biol Psychiatry 1992;31:112-118
44. Nonacs RM, Scares CN, Viguera AC, et al. Bupropion SR for the treatment of postpartum depression: a pilot study. Int J Neuropsychopharmacol 2005;1-5 [Epub ahead of print]
45. Li SW, Yan HQ. Maprotiline (Ludiomil) treatment of mental depression: a clinical report of 65 cases. Proc Chin Acad Med Sci Peking Union Med Coll 1989;4:139-141
46. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-258
47. Bymaster FP, Zhang W, Carter PA. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002;160:353-361
48. Feighner JP. Mechanism of action of antidepressant medications. J Clin Psychiatry 1999;60(suppl 4):4-11
49. Silverstone T. Response to bromocriptine distinguishes bipolar from unipolar depression [letter]. Lancet 1984;1:903-904
50. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161: 564-566
51. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56:54-60
52. Lammers CH, Diaz J, Schwartz JC, et al. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000;5:378-388
53. Rocc P, De Leo C, Eva C, et al. Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2002;26: 1155-1160
54. Gambarana C, Ghiglieri O, Taddei I, et al. Imipramine and fluoxetine prevent the stress-induced escape deficits in rats through a distinct mechanism of action. Behav Pharmacol 1995;6:66-73
55. Ossowsk G, Nowak G, Klenk-Majewskal B, et al. Effect of imipramine on brain D-1 and 5-HT-2A receptors in a chronic unpredictable stress model in rats. Pol J Pharmacol 2002;54:89-93
56. Ainsworth K, Smith SE, Zetterstrom TS, et al. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl) 1998; 140:470-477
57. Fatemi SH, Stary JM, Earle JA, et al. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res 2005;72:109-122
58. Pralong E, Magistretti P, Stoop R. Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. Prog Neurobiol 2002;67:173-202
59. Bezchlibnyk Y, Young LT. The neurobiology of bipolar disorder: focus on signal transduction pathways and the regulation of gene expression. Can J Psychiatry 2002;47:135-148
60. Popoli M, Brunello N, Perez J, et al. Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J Neurochem 2000;74:21-33
61. Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260-265
62. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapihe-fluoxetine combination in the treatment of bipolar I depression [published erratum: Arch Gen Psychiatry 2004;61:176]. Arch Gen Psychiatry 2003;60:1079-1088
63. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. In press
64. Gefvert O. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 1998;135:119-126
65. 2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001;11:105-110
66. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology (Berl) 2002;161:263-270
67. 1A receptor agonism. Brain Res 2002;956:349-357
68. Bymaster FP, Nelson DL, DeLapp NW, et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine HI and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999;37:107-122
69. Seager MA, Barth VN, Phebus LA, et al. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology (Berl) 2005 Feb 18 [Epub ahead of print]
70. Pira L, Mongeau R, Pani L. The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol 2004;504:61-64
71. Blake TJ, Tillery CE, Reynolds GP. Antipsychotic drug affinities at alpha2-adrenoceptor subtypes in post-mortem human brain. J Psychopharmacol 1998;12:151-154
72. Koch S, Perry KW, Bymaster FP: Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004;46:232-242
73. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38
74. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001;158:360-369
75. Stip E. Novel antipsychotics: issues and controversies: typicality of atypical antipsychotics. J Psychiatry Neurosci 2000;25:137-153.
76. Comment in: J Psychiatry Neurosci 2000;25:105-107
77. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-559
78. Tohen M, Zhang F, Keck PE, et al. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J Affect Disord 2001;67:133-140
79. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-1226
80. Tauscher J, Kufferle B, Asenbaum S, et al. Striata1 dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002;162:42-49
81. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:285-292
82. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics. drug interactions, and dosing. J Clin Psychiatry 2002; 63(suppl 13):5-11
83. Tascedda F, Lovati E, Blom JM, et al. Regulation of ionotrophic glutamate receptors in the rat brain in response to the atypical antipsychotic Seroquel (quetiapine fumarate). Neuropsychopharmacology 1999;21: 211-217
84. Golembiowska K, Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol 2000;52:441-448
85. Salchner P, Singewald N. Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 2002;43:1238-1248
86. Ohashi K, Hamamura T, Lee Y, et al. Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-adrenoceptors. Neuropsychopharmacology 2000;23:162-169
87. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271:1058-1066